Perceptions and Representations of Vaccination Against COVID-19 : Perceptions and Representations of Vaccination Against COVID-19
SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high:According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19.To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ClinicalTrials.gov - (2022) vom: 02. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 21, 2021, Last downloaded: ClinicalTrials.gov processed this data on December 05, 2022, Last updated: December 07, 2022 |
|---|
| Study ID: |
NCT04896957 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG007637446 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG007637446 | ||
| 003 | DE-627 | ||
| 005 | 20230425190825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210525s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG007637446 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04896957 | ||
| 035 | |a (UBBS_Klinische_Studien)PERCECOVAC | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Perceptions and Representations of Vaccination Against COVID-19 |b Perceptions and Representations of Vaccination Against COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 21, 2021, Last downloaded: ClinicalTrials.gov processed this data on December 05, 2022, Last updated: December 07, 2022 | ||
| 520 | |a SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high:According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19.To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19. | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Respiratory Distress Syndrome | |
| 650 | 2 | |a Respiratory Distress Syndrome, Newborn | |
| 650 | 2 | |a Acute Lung Injury | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 02. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:02 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04896957 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 02 |c 12 | ||